P1‐256: Ribosomal Genes Activity, Apolipoprotein‐E and Interleukin‐6 Polymorphisms in Alzheimer's Disease

Abstract

lorazepam administration, we restricted our attention to the time of peak plasma drug level (2.5 hours). The study design had two independent variables: TOMM40 gene (short vs long; between-subjects) and drug administration (placebo vs 0.5 mg vs 1 mg; within-subjects). We measured the difference from baseline in total recall. Results: We conducted a 2 X 3 repeated-measures ANOVA and observed an interaction between drug administration and TOMM40 (p ¼ .022). Pairwise comparisons indicated that poly-T length did not influence memory performance when placebo was administered, but was associated with worse recall when lorazepam was administered, both for 0.5 mg (p ¼ .004) and 1.0 mg (p ¼ .001) doses. Conclusions: Our pilot data suggest that variants of TOMM40 may serve as pharmacodynamic predictors of drug-induced memory dysfunction in e4 negative individuals, most of whom had the e3/e3 genotype. Given that the frequency of e3/e3 in the general population is over 55%, this biomarker could have important clinical implications.